It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The objective of this study was to retrospectively evaluate preoperative imaging modalities for localization of parathyroid adenomas with a view to enable minimally invasive parathyroidectomy and in particular, to consider the contribution of 18F-fluorocholine-PET/CT. 104 patients with primary hyperparathyroidism, who underwent parathyroid surgery in a single centre during a 6-year period were included. Of these, 103 underwent ultrasound, 97 99mTc-Pertechnetate/SestaMIBI-SPECT, 20 MRI and 30 18F-fluorocholine-PET/CT. Based on surgical findings, sensitivities and specificities for correct lateralisation in orthotopic locations were: for ultrasound 0.75 (0.65–0.83) and 0.89 (0.81–0.94), for 99mTc-MIBI-SPECT 0.57 (0.46–0.67) and 0.97 (0.91–0.99), for MRI 0.60 (0.36–0.81) and 0.83 (0.59–0.96) and for 18F-fluorocholine-PET/CT 0.90 (0.73–0.98) and 0.90 (0.73–0.98). Correctly lateralized adenomas were significantly larger than those not found with ultrasound (p = 0.03) and SPECT (p = 0.002). Pre-operative PTH-levels were higher in single adenomas detected by scintigraphy than in those not (p = 0.02). 64 patients could be treated with a minimally invasive procedure. Cure after parathyroidectomy was obtained in 94% of patients. 18F-Fluorocholine-PET/CT could be shown to be a highly accurate modality to localize parathyroid adenomas preoperatively, obviating the need for total exploration in the majority of patients in whom ultrasound and scintigraphic results are discordant or both negative.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 AZ Sint-Jan, Otorhinolaryngology-Head and Neck Surgery, Bruges, Belgium (GRID:grid.420036.3) (ISNI:0000 0004 0626 3792)
2 AZ Sint-Jan, Internal Medicine, Endocrinology, Bruges, Belgium (GRID:grid.420036.3) (ISNI:0000 0004 0626 3792)
3 University Hospitals Leuven, Otorhinolaryngology-Head and Neck Surgery, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338); Leuven Cancer Institute, KU Leuven, Department of Oncology, Section Head and Neck Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
4 Ghent University Hospital, Nuclear Medicine, Ghent, Belgium (GRID:grid.410566.0) (ISNI:0000 0004 0626 3303)
5 AZ Sint-Jan, Nuclear Medicine, Bruges, Belgium (GRID:grid.420036.3) (ISNI:0000 0004 0626 3792)